Two Sigma Investments’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Two Sigma Investments’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-21,083	Closed	-$15.6K	–	3478
2023 Q4	$15.6K	Buy	+21,083	New	+$15.4K	﹤0.01%	3061
2022 Q2	–	Sell	-511	Closed	-$19K	–	3056
2022 Q1	$19K	Buy	+511	New	+$17.7K	﹤0.01%	2528
2021 Q4	–	Sell	-4,290	Closed	-$310K	–	5035
2021 Q3	$310K	Sell	4,290 -4,957	-54%	-$379K	﹤0.01%	3647
2021 Q2	$886K	Buy	9,247 +4,631	+100%	+$512K	﹤0.01%	2588
2021 Q1	$682K	Buy	+4,616	New	+$837K	﹤0.01%	2650
2020 Q3	–	Sell	-571	Closed	-$100K	–	3672
2020 Q2	$100K	Buy	+571	New	+$95.6K	﹤0.01%	2786

Other funds holding NBSE

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

CMU

Carnegie Mellon University Pittsburgh, Pennsylvania $64.3M AUM 35.71% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

Two Sigma Investments's NBSE Position: Q1 2024 in Review

Two Sigma Investments sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q1 2024, closing a stake of 21,083 shares — an estimated $15.6K sold.

Two Sigma Investments first reported a position in NBSE in Q2 2020 and held it in 6 quarters. The position peaked at $886K in Q2 2021. 19 funds tracked by Wall St. Rank hold NBSE as of Q1 2024.

Two Sigma Investments reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Two Sigma Investments sold 21,083 NeuBase Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $15.6K.
Two Sigma Investments first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2020 and held it in 6 quarters.
Two Sigma Investments's NeuBase Therapeutics, Inc. Common Stock position peaked at $886K in Q2 2021.
19 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Two Sigma Investments's 13F filing for Q1 2024, filed 15 May 2024.